KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Mizoram appoints Youth for Action as the Interfacing Agency for implementing the ABDM Microsite in Aizawl
Oteseconazole Capsules were found to be safe and more effective than fluconazole
The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Marks the World Head & Neck Cancer Day at the OCTF Conference
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
Subscribe To Our Newsletter & Stay Updated
